Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

ABSTRACT: Using specimens from a phase 1b trial of the RV144 regimen in HIV-1-uninfected South Africans (HVTN 097), we profiled innate responses to the first ALVAC-HIV immunization. PBMC transcriptional responses peaked 1 day post-vaccination. Type I and II interferon signaling pathways were activated, as were innate pathways critical for adaptive immune priming.

ORGANISM(S): Homo sapiens

PROVIDER: GSE164366 | GEO | 2021/03/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

CHIP-Seq analysis of CREB1 binding after ALVAC vaccination in NHP

Project description:The RV144 HIV vaccine trial remains the only study to demonstrate significant protection from future HIV-1 acquisition. One of the key components of the RV144 vaccine was the use of the canarypox vector ALVAC as the priming component. Since AIDSVAX, the booster component, alone failed to provide protection we hypothesized that the ALVAC prime contributed significantly to the generation of protection. To test this, we designed a NHP immunogenicity trial to mechanistically link ALVAC vaccination with the magnitude of V1V2 titers, the most significant immune correlate of reduced HIV-1 acquisition in RV144. Our objective was to use a systems biology approach to identify the transcription factors, target genes and immune pathways which were being induced by ALVAC vaccination and associated with higher V1V2 titers. We identified the transcription factor CREB1 and its target genes as rapidly induced by ALVAC in multiple immune subsets and that CREB1 drives the expression and activation of a network of other TFs which are critical for modulating immune responses. Pathways induced by this ALVAC-CREB1 axis include lymphocyte/leukocyte migration, lymphocyte differentiation, antigen processing and presentation, T cell co-stimulation and cytokine signaling.

2021-07-25 | GSE180748 | GEO

Microarray analysis of correlates of vaccine immunogenecity following ALVAC vaccination in NHP in Study 36

2021-07-26 | GSE180677 | GEO

CHIP-Seq analysis of CREB1 binding after ALVAC vaccination in Human PBMC

2021-07-25 | GSE180747 | GEO

Transcriptomic profiling of RV144 trial participants after vaccination with ALVAC-HIV and AIDSVAX B/E. [rv144]

Project description:The RV144 clinical trial evaluated the efficacy of a vaccine regimen that included ALVAC-HIV prime and AIDSVAX boost in preventing HIV-1 acquisition. The vaccine reduced the risk of HIV-1 acquisition by 31.2%; however the mechanisms that led to the protection induced by this vaccine remain poorly understood. Our objectives were to identify transcriptional correlates and mechanisms that could explain the reduced acquisition conferred by the vaccine. We assessed the transcriptomic profile of HIV Env stimulated peripheral blood mononuclear cells collected from 223 participants two weeks after vaccination and from 40 placebo recipients.

2019-02-15 | GSE103733 | GEO

Transcriptomic profiling of RV144 trial participants before and after vaccination with ALVAC-HIV and AIDSVAX B/E.[rv144pilot]

2019-02-15 | GSE103671 | GEO

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Project description:Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

| PRJNA690118 | ENA

Transcriptomic profiling of rhesus macaques vaccinated with Ad26/ALVAC+gp120 or DNA/ALVAC+gp120

Project description:We contrasted innate and adaptive immune responses of HIV vaccine candidates of varying efficacy in macaques that shared the ALVAC+gp120 protein boost with an ALVAC, DNA or Ad26 prime modality. The vaccine efficacies of the DNA/ALVAC+gp120 and ALVAC/ALVAC+gp120 vaccine regimens, both protective, were associated with qualitative temporal-spatial differences in the innate CD14+ and CD16+ cells in blood and tissues. The activation of hypoxia and the inflammasome in CD14+ DR+ CD16- classical monocytes and CD4+ Th2 responses correlated with a decreased risk of SIVmac251 acquisition. CD4+ Th2 cells, in turn, correlated with mucosal NKp44+ cells and mucosal protective antibodies to V2. In contrast, the Ad26/ALVAC+gp120 vaccine resulted in increased de novo differentiated CX3CR1+ CD163+ macrophages in lymph nodes, increased CD4+ Th17 cells in blood and rectal mucosa, and a lack vaccine efficacy. These data posit that the engagement of classical monocytes and inflammasome activation is central for the elicitation of protective innate and adaptive responses by the ALVAC-based HIV vaccine platform.

2018-02-23 | GSE108011 | GEO

DNA methylation analysis of PBMC from HIV and HIV/TB co-infected patients

Project description:Genome wide DNA methylation profiling of PBMC from South African patients either infected with HIV only or coinfected with HIV and tuberculosis (TB). The Illumina Infinium 27k Human DNA methylation Beadchip was used to obtain DNA methylation profiles from PBMC samples. Samples included 19 HIV patients and 20 HIV/TB co-infected patients.

2014-03-05 | GSE50835 | GEO

Homo sapiens

Project description:Transcriptomic profiling of RV144 trial participants after vaccination with ALVAC-HIV and AIDSVAX B/E. [rv144]

| PRJNA406921 | ENA

DNA methylation analysis of PBMC from HIV and HIV/TB co-infected patients

2014-03-05 | E-GEOD-50835 | biostudies-arrayexpress